Gilead Sciences, Inc. (GILD) Sees Significant Decrease in Short Interest

Gilead Sciences, Inc. (NASDAQ:GILD) was the target of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 19,394,953 shares, a drop of 13.4% from the February 15th total of 22,395,137 shares. Based on an average daily volume of 7,055,606 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.4% of the company’s stock are short sold.

GILD has been the topic of several recent research reports. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective on the stock in a research report on Monday, February 5th. Leerink Swann cut their price objective on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 7th. BMO Capital Markets raised their price objective on shares of Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research report on Thursday, February 8th. Maxim Group set a $94.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, February 6th. Finally, Bank of America raised their price objective on shares of Gilead Sciences from $82.00 to $87.00 and gave the company a “neutral” rating in a research report on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $88.61.

In related news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.87, for a total transaction of $1,108,050.00. Following the completion of the sale, the executive vice president now directly owns 64,613 shares in the company, valued at $4,772,962.31. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total transaction of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 430,268 shares of company stock valued at $34,074,395. 1.30% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. Keel Point LLC increased its position in Gilead Sciences by 0.4% during the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock worth $221,000 after acquiring an additional 12 shares during the period. Paradigm Financial Advisors LLC increased its position in Gilead Sciences by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 26 shares during the period. Princeton Portfolio Strategies Group LLC increased its position in Gilead Sciences by 0.4% during the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after acquiring an additional 41 shares during the period. Auxier Asset Management increased its position in Gilead Sciences by 1.4% during the second quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock worth $479,000 after acquiring an additional 96 shares during the period. Finally, Edmonds Duncan Registered Investment Advisors LLC increased its position in Gilead Sciences by 1.6% during the second quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 6,386 shares of the biopharmaceutical company’s stock worth $452,000 after acquiring an additional 100 shares during the period. 77.96% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences (NASDAQ GILD) opened at $81.72 on Wednesday. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a market cap of $107,050.00, a P/E ratio of 10.63, a PEG ratio of -1.86 and a beta of 1.24. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same quarter last year, the firm posted $2.70 earnings per share. The company’s quarterly revenue was down 18.7% compared to the same quarter last year. sell-side analysts forecast that Gilead Sciences will post 6.21 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is 27.05%.

ILLEGAL ACTIVITY NOTICE: “Gilead Sciences, Inc. (GILD) Sees Significant Decrease in Short Interest” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2018/03/14/gilead-sciences-inc-gild-sees-significant-decrease-in-short-interest.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply